Harvard Apparatus Regenerative Technology Inc. - HRGN STOCK NEWS

Harvard Apparatus Regenerative Technology (OTCQB: HRGN) has appointed Mao Zhang as an independent director to its Board of Directors. Zhang, the Founder and CEO of StellarS Capital, brings over 15 years of experience in financial markets, including hedge fund and private equity expertise. This appointment aims to strengthen the company's business innovation, strategy, and finance areas.

Jerry He, chairman of Harvard Apparatus Regenerative Technology, expressed confidence that Zhang's deep business and investment experience will be instrumental in pursuing the company's mission to address unmet patient needs. Zhang, in turn, stated his enthusiasm for joining the board at this important stage of clinical development, highlighting the company's potential to develop novel cell therapies that could change and extend patients' lives through regenerated organs.

Harvard Apparatus Regenerative Technology (OTCQB: HRGN) has secured a $5 million financing through a private placement of shares to a new investor. The funds will accelerate the clinical development of HRGN's lead product, the HRGN Esophageal Implant (BEI). The FDA has approved a ten-patient phase one and phase two clinical trial to study esophageal repair in adults affected by cancer or injury. There's potential to expand the trial to include pediatric subjects with esophageal birth defects. The private placement involves the sale of 1,388,888 shares at $3.60 per share. CEO Jerry He expressed enthusiasm about the new strategic investor and the opportunity to advance HRGN's clinical trials and pipeline development.

Harvard Apparatus Regenerative Technology (OTCQB: HRGN) has reported its first quarter 2024 financial results and recent business highlights. The company, which is developing organ regeneration technology, entered into a $1.5 million PIPE financing agreement that closed on April 15, 2024. Additionally, it received $0.5 million in convertible debt from its CEO in February 2024.

For Q1 2024, HRGN reported a net loss of $2.0 million, or $0.15 per share, an improvement from the $3.0 million loss, or $0.24 per share, in Q1 2023. This was mainly due to a $1.5 million share-based compensation expense incurred in Q1 2023, which was not repeated in 2024. However, increased preclinical and clinical trial activities in Q1 2024 offset some of the gains.

As of March 31, 2024, the company had $0.3 million in operating cash. It used $1.0 million in operational cash during the quarter and raised $0.3 million through financing activities. The company also reported a $0.5 million debt financing from a related party.

Harvard Apparatus Regenerative Technology, Inc. announced several collaborations and milestones, including a research partnership with the McGowan Institute for Regenerative Medicine, a clinical trial site activation, and an orphan disease application approval. The company also reported financial results for the fourth quarter and full year 2023, showing a net loss increase year-over-year.

Harvard Apparatus Regenerative Technology, Inc. (HRGN) has officially executed a sponsored research agreement with the University of Pittsburgh and UPMC to develop regenerative therapies for organ and tissue failure. The program will focus on repairing the colon following colectomy, a surgical procedure for conditions like cancer and inflammatory bowel disease.

Harvard Apparatus Regenerative Technology, Inc. (OTCQB: HRGN) has officially executed a Sponsored Research Agreement (SRA) with Hugh Taylor, MD, chair of Obstetrics, Gynecology & Reproductive Sciences at Yale School of Medicine. The program will focus on the use of Harvard Apparatus Regenerative Technology’s cell-based scaffold platform to restore fertility by repairing uterine tissue in a mouse model of uterine damage. IUAs have a debilitating impact on the health and quality of life in women of childbearing age while the economic burden is substantial. This initiative aims to treat infertility in women that require repair or regeneration of their uterine tissue, providing a significant advancement in women’s health.

Harvard Apparatus Regenerative Technology, Inc. (HRGN) Announces Financial Results and Operating Highlights, Including Expansion of Clinical Trial Sites and European Medicines Agency Approval

HRGN: Harvard Apparatus Regenerative Technology, Inc. to Release Q3 2023 Financial Results on November 13, 2023. The clinical-stage biotechnology company will discuss financial results and business updates during a conference call and webcast at 9:00 AM ET. Q&A session included.

Harvard Apparatus Regenerative Technology activates second site for clinical trial on severe esophageal disease, accelerating development timelines.